NCT00390832View on ClinicalTrials.gov

Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3)

PHASE3CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Myocardial InfarctionAngioplasty, Transluminal, Percutaneous Coronary
Interventions
DRUG

Erythropoietin

33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU

OTHER

Placebo

Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.

Trial Locations (2)

80636

Deutsches Herzzentrum Muenchen, Munich

81675

1. Medizinische Klinik, Klinikum rechts der Isar, Munich

All Listed Sponsors
lead

Deutsches Herzzentrum Muenchen

OTHER

NCT00390832 - Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3) | Biotech Hunter | Biotech Hunter